Drug Trial Radar · NCT00664742
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
Last checked: Nov 19, 2026Latest source record: May 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
614
Actual
Start
Sep 2006
Primary completion
Oct 2007
Study completion Oct 2007
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome
Conditions
- Metabolic Syndrome
Interventions
Fluvastatin XL®Drug
Fluvastatin extended release 80 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Cholesterol (TC), High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides (TG) Levels From Baseline to Week-6Time frame: Baseline,6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Götzepe Education and Research Hospital
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.